Price Target Changed • May 03
Price target decreased by 7.7% to AU$0.92 Down from AU$1.00, the current price target is an average from 2 analysts. New target price is 20% below last closing price of AU$1.15. The company is forecast to post a net loss per share of NZ$0.028 next year compared to a net loss per share of NZ$0.039 last year. Announcement • Apr 11
Volpara Health Technologies Limited Launches MQSA Compliance Software at the Society for Breast Imaging Symposium Volpara Health Technologies Limited debuted a new central, digital destination to manage mammography systems, staff credentials and professional development in support of compliance with the Food & Drug Administration's Mammography Quality Standards Act (MQSA). Volpara® Quiver™ software is featured at the Society for Breast Imaging's (SBI) annual symposium alongside the company's suite of solutions for assessing breast density, mammography quality and evaluating cancer risk. Quiver helps quality assurance leaders ensure everything is in order well in advance of inspection day. Quiver set up is auto populated with clinic, mammography system and technologist activity from Volpara® Analytics™ software. The software is accessible from any web browser and provides a clinic by clinic look at technologists' continuing education records and mammography system quality assurance documentation. Technologists can upload their own records and email notifications can alert staff when their credits are about to expire. Free credits are also available through Volpara® Hive™, an online community exclusively for Volpara customers. All documentation can be presented to inspectors digitally or printed. Price Target Changed • Mar 26
Price target decreased by 13% to AU$1.00 Down from AU$1.15, the current price target is an average from 3 analysts. New target price is 12% below last closing price of AU$1.14. The company is forecast to post a net loss per share of NZ$0.024 next year compared to a net loss per share of NZ$0.039 last year. Announcement • Dec 15
Lunit Inc. (KOSDAQ:A328130) agreed to acquire Volpara Health Technologies Limited (ASX:VHT) from Harbour Asset Management Limited and others for AUD300 million. Lunit Inc. (KOSDAQ:A328130) agreed to acquire Volpara Health Technologies Limited (ASX:VHT) from Harbour Asset Management Limited and others for AUD300 million on December 13, 2023. Volpara shareholder approval will be sought at a Scheme meeting of shareholders expected to be held in early Q2 2024. The proposed Scheme is subject to Volpara shareholder and Court approval, approval of the New Zealand Overseas Investment Office, a ‘material adverse change’ condition, and other conditions as detailed in the Scheme Implementation Agreement. The Board is unanimous in its view that this transaction is in the best interests of Volpara shareholders. The Board unanimously recommends that shareholders vote in favour of the proposed Scheme, subject to the Scheme price being within or above the Independent Adviser’s valuation range for Volpara’s shares and in the absence of a superior proposal. The Acquirer will at Implementation have available to it on an unconditional basis sufficient cash resources (whether from internal cash reserves or external funding arrangements or a combination of both) to satisfy the Acquirer s obligations to pay the Consideration in accordance with its obligations under this agreement, the Scheme and the Deed Poll. If all the conditions are satisfied, the proposed Scheme is expected to be implemented in Q2 2024. Price Target Changed • Dec 15
Price target increased by 14% to AU$1.15 Up from AU$1.01, the current price target is an average from 2 analysts. New target price is 5.0% above last closing price of AU$1.10. Stock is up 92% over the past year. The company is forecast to post a net loss per share of NZ$0.024 next year compared to a net loss per share of NZ$0.039 last year. Reported Earnings • Nov 23
First half 2024 earnings released: NZ$0.017 loss per share (vs NZ$0.021 loss in 1H 2023) First half 2024 results: NZ$0.017 loss per share (improved from NZ$0.021 loss in 1H 2023). Revenue: NZ$19.8m (up 18% from 1H 2023). Net loss: NZ$4.41m (loss narrowed 17% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Price Target Changed • Nov 22
Price target decreased by 16% to AU$1.01 Down from AU$1.20, the current price target is an average from 2 analysts. New target price is 41% above last closing price of AU$0.71. Stock is up 7.5% over the past year. The company is forecast to post a net loss per share of NZ$0.023 next year compared to a net loss per share of NZ$0.039 last year. Breakeven Date Change • Nov 22
Forecast breakeven date pushed back to 2026 The 2 analysts covering Volpara Health Technologies previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 79% per year to 2025. The company is expected to make a profit of NZ$15.1m in 2026. Average annual earnings growth of 98% is required to achieve expected profit on schedule. New Risk • Oct 18
New major risk - Revenue and earnings growth Earnings have declined by 4.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Announcement • Oct 10
Volpara Health Technologies Limited to Report Q2, 2024 Results on Oct 17, 2023 Volpara Health Technologies Limited announced that they will report Q2, 2024 results on Oct 17, 2023 Announcement • Aug 29
An Unknown buyer acquired 4% stake in Reveal DX fromVolpara Health Technologies Limited (ASX:VHT). An Unknown buyer acquired 4% stake in Reveal DX fromVolpara Health Technologies Limited (ASX:VHT) on August 28, 2023.An Unknown buyer completed the acquisition of 4% stake in Reveal DX fromVolpara Health Technologies Limited (ASX:VHT) on August 28, 2023. Announcement • Jul 24
Volpara Health Technologies Limited, Annual General Meeting, Aug 17, 2023 Volpara Health Technologies Limited, Annual General Meeting, Aug 17, 2023, at 10:01 E. Australia Standard Time. Agenda: To consider Annual Report and Report of the Auditor; to consider re-election of Karin Lindgren and Roger Allen as a Directors of the Company; to consider approval for issue of options to Mark Bouw; to consider approval of Long Term Incentive Plan; to consider ratification of the prior issue of securities under the LTIP; to consider Issue of Restricted Stock Units to the Managing Director; to consider Amendment of the Company’s Constitution; to consider Approval of Additional 10% Placement Capacity; and to consider any other matters. Announcement • Jul 12
Volpara Health Technologies Limited to Report Q1, 2024 Results on Jul 21, 2023 Volpara Health Technologies Limited announced that they will report Q1, 2024 results on Jul 21, 2023 Reported Earnings • May 26
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: NZ$0.04 loss per share (improved from NZ$0.065 loss in FY 2022). Revenue: NZ$35.0m (up 34% from FY 2022). Net loss: NZ$9.80m (loss narrowed 40% from FY 2022). Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 23%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Major Estimate Revision • May 25
Consensus EPS estimates fall by 137%, revenue upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from NZ$40.0m to NZ$42.5m. Forecast EPS reduced from -NZ$0.0098 to -NZ$0.0233 per share. Healthcare Services industry in Australia expected to see average net income growth of 27% next year. Consensus price target up from AU$1.16 to AU$1.20. Share price fell 9.9% to AU$0.69 over the past week. Announcement • Jan 03
Volpara Health Technologies Limited Appoints Mark Bouw as Independent, Non-Executive Director Volpara Health Technologies Limited announced the appointment of Mark Bouw to the Volpara Board of Directors as an independent, Non-Executive Director, effective 1 January 2023. Mark is a highly experienced senior healthcare CEO who brings a wealth of international education and experience in strategy and growth for healthcare and technology companies. As founder and Managing Director of the Mark Bouw Group Pty Ltd., a leading boutique professional services company based in Melbourne, Australia, Mark's clients include global C-suites, capital funds and private equity investors, and entrepreneurs. He is a visiting consultant at Stanford University's Graduate Business School Seed Program in the United States and is a visiting mentor for Stanford's Ignite program. Breakeven Date Change • Dec 29
Forecast breakeven date pushed back to 2025 The 2 analysts covering Volpara Health Technologies previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 59% per year to 2024. The company is expected to make a profit of NZ$4.93m in 2025. Average annual earnings growth of 94% is required to achieve expected profit on schedule. Reported Earnings • Nov 23
First half 2023 earnings released: NZ$0.02 loss per share (vs NZ$0.034 loss in 1H 2022) First half 2023 results: NZ$0.02 loss per share (improved from NZ$0.034 loss in 1H 2022). Revenue: NZ$16.9m (up 37% from 1H 2022). Net loss: NZ$5.29m (loss narrowed 38% from 1H 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Australia. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Announcement • Nov 23
Volpara Health Technologies Limited Provides Revenue Guidance for the Full Year 2023 Volpara Health Technologies Limited announced that while concentrating on delivering the updated revenue guidance of NZD 33.5 Million - NZD 35 Million (or 28%-34%) for the full year 2023, they continue with strategy of driving for profitable growth based on focus: most profitable products, most lucrative markets, and providing the best value for elephant-sized customers. Breakeven Date Change • Nov 16
Forecast breakeven date moved forward to 2024 The 3 analysts covering Volpara Health Technologies previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 57% to 2023. The company is expected to make a profit of NZ$1.83m in 2024. Average annual earnings growth of 97% is required to achieve expected profit on schedule. Major Estimate Revision • Oct 28
Consensus estimates of losses per share improve by 14% The consensus outlook for earnings per share (EPS) in 2023 has improved. 2023 revenue forecast increased from NZ$33.8m to NZ$35.2m. EPS estimate increased from -NZ$0.04 per share to -NZ$0.03 per share. Healthcare Services industry in Australia expected to see average net income growth of 31% next year. Consensus price target of AU$0.95 unchanged from last update. Share price rose 13% to AU$0.68 over the past week. Breakeven Date Change • Oct 28
Forecast breakeven date moved forward to 2024 The 3 analysts covering Volpara Health Technologies previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 49% to 2023. The company is expected to make a profit of NZ$8.97m in 2024. Average annual earnings growth of 88% is required to achieve expected profit on schedule. Announcement • Oct 21
Volpara Health Technologies Limited Appoints Fred Struve as Joint Company Secretary Volpara Health Technologies Limited announced that Fred Struve has been appointed as Joint Company Secretary, effective immediately, in addition to him continuing his role as General Counsel. Fred has held the position of General Counsel since September 2021. Breakeven Date Change • Oct 18
Forecast to breakeven in 2025 The 3 analysts covering Volpara Health Technologies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$1.16m in 2025. Average annual earnings growth of 90% is required to achieve expected profit on schedule. Announcement • Oct 03
Volpara Health Technologies Limited Announces the Appointment of Teri Thomas as Managing Director Volpara Health Technologies Limited announced the appointment of Teri Thomas, Chief Executive Officer of Volpara, to the Board as Managing Director, effective 1 October 2022. Thomas was appointed CEO in April 2022. Her remuneration and other contractual arrangements remain unchanged from that disclosed previously. Announcement • Sep 21
Volpara Health Launches Professional Services to Accelerate Success for High-Risk Cancer Programs Volpara Health announced the launch of its new comprehensive Professional Services offering to help its Risk Pathways customers maximize the value of their high-risk cancer assessment programs. Volpara Risk Pathways software has been used by more than 1,000 providers across the United States to identify, manage, and improve outcomes for patients at elevated risk for developing cancer. Prominent medical associations now recommend risk assessment as a strategy to help detect breast cancer earlier, when it is more treatable.1 Accordingly, more and more healthcare providers are instituting high-risk programs to identify at a younger age those women who will benefit from additional screening and prevention techniques. As setting up a high-risk program can involve many challenges, breast care providers can benefit from the specialized expertise and support required to establish a program and achieve their clinical, financial, and operational goals. From inception to optimization, Volpara Professional Services helps programs achieve long-term success, offering expertise across the spectrum of essential program elements: Strategy development; Program implementation; Workflow optimization; Physician and staff alignment; Patient education; Marketing support; Program evaluation; Return-on-investment frameworks. Breakeven Date Change • Jul 29
Forecast breakeven date pushed back to 2025 The 4 analysts covering Volpara Health Technologies previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 78% per year to 2024. The company is expected to make a profit of NZ$2.96m in 2025. Average annual earnings growth of 89% is required to achieve expected profit on schedule. Recent Insider Transactions • Jun 18
Key Executive recently bought AU$67k worth of stock On the 15th of June, Paul Robert Reid bought around 115k shares on-market at roughly AU$0.58 per share. This was the largest purchase by an insider in the last 3 months. This was Paul Robert's only on-market trade for the last 12 months. Buying Opportunity • Jun 02
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 1.4%. The fair value is estimated to be AU$0.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 5.4%. Revenue is forecast to grow by 33% in a year. Earnings is forecast to grow by 39% in the next year. Price Target Changed • May 31
Price target decreased to AU$1.15 Down from AU$1.62, the current price target is an average from 4 analysts. New target price is 52% above last closing price of AU$0.76. Stock is down 42% over the past year. The company is forecast to post a net loss per share of NZ$0.041 next year compared to a net loss per share of NZ$0.065 last year. Breakeven Date Change • May 27
Forecast breakeven date pushed back to 2025 The 2 analysts covering Volpara Health Technologies previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 64% per year to 2024. The company is expected to make a profit of NZ$6.90m in 2025. Average annual earnings growth of 85% is required to achieve expected profit on schedule. Breakeven Date Change • May 26
Forecast breakeven date pushed back to 2025 The 2 analysts covering Volpara Health Technologies previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of NZ$17.7m in 2025. Average annual earnings growth of 60% is required to achieve expected profit on schedule. Breakeven Date Change • Apr 19
No longer forecast to breakeven The 2 analysts covering Volpara Health Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of NZ$2.56m in 2024. New consensus forecast suggests the company will make a loss of NZ$5.31m in 2024. Price Target Changed • Feb 02
Price target decreased to AU$1.62 Down from AU$1.77, the current price target is an average from 2 analysts. New target price is 79% above last closing price of AU$0.91. Stock is down 41% over the past year. The company is forecast to post a net loss per share of NZ$0.065 next year compared to a net loss per share of NZ$0.071 last year. Breakeven Date Change • Jan 20
No longer forecast to breakeven The 2 analysts covering Volpara Health Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of NZ$3.55m in 2024. New consensus forecast suggests the company will make a loss of NZ$3.89m in 2024. Reported Earnings • Nov 24
First half 2022 earnings: EPS and revenues exceed analyst expectations First half 2022 results: NZ$0.034 loss per share (up from NZ$0.036 loss in 1H 2021). Revenue: NZ$12.3m (up 30% from 1H 2021). Net loss: NZ$8.51m (loss narrowed 4.0% from 1H 2021). Revenue exceeded analyst estimates by 3.4%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Earnings per share (EPS) surpassed analyst estimates by 22%. Over the next year, revenue is forecast to grow 44%, compared to a 210% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 1% per year. Breakeven Date Change • Nov 24
No longer forecast to breakeven The 2 analysts covering Volpara Health Technologies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of NZ$3.77m in 2024. New consensus forecast suggests the company will make a loss of NZ$3.80m in 2024. Price Target Changed • Oct 26
Price target increased to AU$2.00 Up from AU$1.73, the current price target is an average from 2 analysts. New target price is 59% above last closing price of AU$1.26. Stock is down 11% over the past year. The company is forecast to post a net loss per share of NZ$0.05 next year compared to a net loss per share of NZ$0.071 last year. Executive Departure • Aug 19
Non-Executive Director Monica Saini has left the company On the 18th of August, Monica Saini's tenure as Non-Executive Director ended after 3.0 years in the role. As of June 2021, Monica still personally held 80.00k shares (AU$93k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. Price Target Changed • Jul 27
Price target decreased to AU$1.74 Down from AU$1.87, the current price target is an average from 2 analysts. New target price is 53% above last closing price of AU$1.14. Stock is down 15% over the past year. Announcement • Jul 15
Volpara Grows Patent Collection with Recently Granted European Protection of Image Quantification Volpara Health Technologies has recently been granted another patent by the European Patent Office, raising the total number of patents to 98. This
latest patent, effective across 25 European countries, outlines the Volpara method of image quantification, used in multiple instances across the Volpara Breast Health Platform product suite. This latest patent highlights improved analysis of several quantitative measures from low-dose images, enabling highly accurate assessment of a woman's breast composition at an early age, and calculation of her baseline risk of breast cancer. In addition to improving outcomes for women, the improvements will help optimize clinical workflow. Research studies are beginning to suggest patients receive a baseline mammogram to assess their breast density and breast cancer risk before they reach the screening age of 40. A patient who receives a high breast cancer risk score may be directed to begin annual screenings earlier than usual. One of the concerns with offering women between the ages of 25 and 30 a baseline screening exam has been the effect of the exam's radiation. High-sensitivity, low-dose imaging has the potential to offer patients a way around this issue--a solution in line with Volpara's aim to achieve personalized breast cancer screening for all women. Recent Insider Transactions • Jun 16
Insider recently sold AU$122k worth of stock On the 10th of June, Monica Saini sold around 100k shares on-market at roughly AU$1.21 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Major Estimate Revision • Jun 02
Consensus EPS estimates fall to -NZ$0.046 The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from NZ$27.1m to NZ$26.7m. Losses expected to increase from -NZ$0.036 to -NZ$0.046. Healthcare Services industry in Australia expected to see average net income growth of 33% next year. Consensus price target broadly unchanged at AU$1.83. Share price fell 2.7% to AU$1.27 over the past week. Breakeven Date Change • May 29
Forecast breakeven pushed back to 2024 The 2 analysts covering Volpara Health Technologies previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 59% per year to 2023. The company is expected to make a profit of NZ$3.00m in 2024. Average annual earnings growth of 81% is required to achieve expected profit on schedule. Reported Earnings • May 29
Full year 2021 earnings released: NZ$0.07 loss per share (vs NZ$0.097 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: NZ$19.7m (up 57% from FY 2020). Net loss: NZ$17.5m (loss narrowed 14% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Price Target Changed • May 28
Price target decreased to AU$1.84 Down from AU$1.99, the current price target is an average from 2 analysts. New target price is 41% above last closing price of AU$1.30. Stock is down 8.1% over the past year. Price Target Changed • Mar 31
Price target increased to AU$1.99 Up from AU$1.74, the current price target is an average from 2 analysts. New target price is 53% above last closing price of AU$1.30. Stock is up 15% over the past year. Announcement • Mar 13
Volpara Health Technologies Signs Highest Value Contract to Date Via CRA Health Volpara Health Technologies announced that it has signed its highest value contract to date via its recently acquired CRA Health subsidiary. The contract, worth over USD 400,000 per year of Annual Recurring Revenue covers the provision of breast cancer risk scores to a large Indiana-based organization that has sites across more than 20 states and runs a major Electronic Health Record system, which makes the deployment and implementation very cost effective. Is New 90 Day High Low • Mar 03
New 90-day low: AU$1.30 The company is down 7.0% from its price of AU$1.40 on 03 December 2020. The Australian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 29% over the same period. Announcement • Feb 02
Volpara Health Technologies Limited (ASX:VHT) acquired CRA Health Services, Inc. for $22 million. Volpara Health Technologies Limited (ASX:VHT) acquired CRA Health Services, Inc. for $22 million on February 2, 2021. Volpara is paying $18 million to acquire all outstanding equity of CRA, with a further $4 million payable upon its meeting key performance targets over the next 18 months. All payments to come out of existing funds. CRA Health reported $3.1 million of revenues for the years ending December 31, 2020.
Volpara Health Technologies Limited (ASX:VHT) completed the acquisition of CRA Health Services, Inc. on February 2, 2021. Price Target Changed • Feb 02
Price target raised to AU$1.81 Up from AU$1.64, the current price target is an average from 3 analysts. The new target price is 18% above the current share price of AU$1.54. As of last close, the stock is down 14% over the past year. Is New 90 Day High Low • Feb 02
New 90-day high: AU$1.54 The company is up 17% from its price of AU$1.31 on 04 November 2020. The Australian market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare Services industry, which is up 27% over the same period. Announcement • Jan 19
Volpara Health Technologies Limited to Report Q3, 2021 Results on Jan 28, 2021 Volpara Health Technologies Limited announced that they will report Q3, 2021 results on Jan 28, 2021 Announcement • Dec 19
Volpara Health Technologies Advises Major Customer Contract It Renewed and Extended in Second Quarter of Fiscal 2021 Is with the US Radiology Group Volpara Health Technologies advised that the major customer contract it renewed and extended in second quarter of fiscal 2021 is with the US Radiology Group. The contract is for a five year term for delivery and ongoing use of the Volpara Breast Health Platform. US Radiology is a fast-growing partnership of physician-led sub-specialised radiology groups dedicated to providing exceptional patient care. US Radiology brings together high-quality sub-specialised radiologists with leading outpatient operational expertise, infrastructure, and state-of-the-art technology support. US Radiology comprises more than 280 radiologists, 3100 team members, and 145 outpatient imaging centres across 14 states in the United States. Reported Earnings • Nov 26
First half 2021 earnings released: NZ$0.036 loss per share The company reported a solid first half result with improved revenues and control over expenses, though losses increased. First half 2021 results: Revenue: NZ$9.47m (up 38% from 1H 2020). Net loss: NZ$8.87m (loss widened 11% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Oct 13
New 90-day high: AU$1.47 The company is up 3.0% from its price of AU$1.42 on 15 July 2020. The Australian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Sep 24
New 90-day low: AU$1.27 The company is down 4.0% from its price of AU$1.32 on 26 June 2020. The Australian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Jul 21
Volpara Health Technologies Limited to Report Q1, 2021 Results on Jul 28, 2020 Volpara Health Technologies Limited announced that they will report Q1, 2021 results at 8:57 PM, GMT Standard Time on Jul 28, 2020 